|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Coordination Polymerization of Lactides, 4^a) the Role of Transesterification in the Copolymerization of L, L-lactide and e caprolactone 显示文摘 | K asperczyk J Bero M | 1993 | Makromol Chem1993，194，3： | 1 |
| 2 | Pharmaceutical industry sponsorship and research outcome and quality:Sys- tematic review 显示文摘 | Lexchin J Bero LA Djulbegovic B | 2003 | BMJ2003，326，： | 1 |
| 3 | Natural products published in 2009 from plants traditionally used to treat malaria 显示文摘 | BERO J QUETIN-LECLERCQ J | 2011 | Planta Med2011，77，6： | 1 |
| 4 | Closing the gap between research and practice : An overview of systematic reviews of interventions to promote the implementation of research findings显示文摘 | Bero LA Grilli R Grimshaw J M et a l | 1998 | BMJ1998，317，： | 1 |
| 5 | 显示文摘 | Kasperczyk J Bero M | 1993 | Makromol Chem1993，194，： | 1 |
| 6 | Disruption of the sleep-- wake cycle and diurnal fluctuation of β- amyloid in mice with Alzheimer's disease pathology显示文摘 | Roh J H Huang Y Bero A W | 2012 | Science Translational Medicine2012，4，15： | 1 |
| 7 | 显示文摘 | Bero M Kasperczyk J | 1996 | Makromol Chem1996，197，： | 1 |
| 8 | Pharmaceutical industry sponsorship and research outcome and quality: systematic review显示文摘 | Lexchin J Bero LA Djulbegovic B | 2003 | BMJ2003，326，7400： | 1 |
| 9 | Stereoselective polymerization of racemic DL-lactide in the presence of butyllithium and butylmagnesium:Structural investigations of the polymers显示文摘 | Kasperczyk J Bero M | 2000 | Polymer2000，41，： | 1 |
| 10 | Moral disen- gagement in the corporate world 显示文摘 | White J Bandura A Bero L | 2009 | Accountability in Re- search2009，16，： | 1 |
| 11 | Application of calcium acetylacetonate to the polymerization of glycolide and copolymerization of glycolide with ε-caprolactone and L-lactide显示文摘 | Dobrzynski P Kasperczyk J Bero M | 1999 | Macromolecules1999，32，： | 1 |
| 12 | Pharmaceutical industry sponsorship and research outcome and quality : systematic review 显示文摘 | Lexchin J Bero LA Djulbegovic B | 2003 | BMJ2003，326，7400： | 1 |
| 13 | Can short-term fasting protect against doxorubicin-induced cardiotoxicity?显示文摘Doxorubicin(Dox) is one of the most effective chemotherapeutic agents used in the treatment of several types of cancer. However the use is limited by cardiotoxicity. Despite extensive investigation into the mechanisms of toxicity and preventative strategies, Dox-induced cardiotoxicity still remains a major cause of morbidity and mortality in cancer survivors. Thus, continued research into preventative strategies is vital. Short-term fasting has proven to be cardioprotective against a variety of insults. Despite the potential, only a few studies have been conducted investigating its ability to prevent Dox-induced cardiotoxicity. However, all show proof-of-principle that short-term fasting is cardioprotective against Dox. Fasting affects a plethora of cellular processes making it difficult to discern the mechanism(s) translating fasting to cardioprotection, but may involve suppression of insulin and insulin-like growth factor-1 signaling with stimulated autophagy. It is likely that additional mechanisms also contribute. Importantly, the literature suggests that fasting may enhance the antitumor activity of Dox. Thus, fasting is a regimen that warrants further investigation as a potential strategy to prevent Dox-induced cardiotoxicity. Future research should aim to determine the optimal regimen of fasting, confirmation that this regimen does not interfere with the antitumor properties of Dox, as well as the underlying mechanisms exerting the cardioprotective effects. | Amie J Dirks-Naylor Samir A Kouzi Sendra Yang Ngan TK Tran Joseph D Bero Raean Mabolo Diep T Phan Stephanie D Whitt Heather N Taylor | 2014 | World Journal of Biological Chemistry2014，5，3： | 1 |
| 14 | A CCD-based optical CT scanner for high- resolution 3D imaging of radiation dose distribu- tions: Equipment specifications, optical simula- tions and preliminary results显示文摘 | DORAN S J KOERKAMP K K BERO M A | 2001 | Physics in Medicine and Biology2001，46，12： | 1 |
| 15 | Effects of acute doxorubicin treatment on hepatic proteome lysine acetylation status and the apoptotic environment显示文摘AIM: To determine if doxorubicin(Dox) alters hepatic proteome acetylation status and if acetylation status was associated with an apoptotic environment. METHODS: Doxorubicin(20 mg/kg; Sigma, Saint Louis, MO; n = 8) or NaCl(0.9%; n = 7) was administered as an intraperitoneal injection to male F344 rats, 6-wk of age. Once animals were treated with Dox or saline, all animals were fasted until sacrifice 24 h later. RESULTS: Dox treatment decreased proteome lysine acetylation likely due to a decrease in histone acetyltransferase activity. Proteome deacetylation may likely not be associated with a proapoptotic environment. Dox did not increase caspase-9,-8, or-3 activation nor poly(adenosine diphosphate-ribose) polymerase-1 cleavage. Dox did stimulate caspase-12 activation, however, it likely did not play a role in apoptosis induction. CONCLUSION: Early effects of Dox involve hepatic proteome lysine deacetylation and caspase-12 activa-tion under these experimental conditions. | Amie J Dirks-Naylor Samir A Kouzi Joseph D Bero Ngan TK Tran Sendra Yang Raean Mabolo | 2014 | World Journal of Biological Chemistry2014，5，3： | 1 |
| 16 | Volume-dependent rate processes in an epoxy resin显示文摘 | Bero C A Plazek D J | 1991 | Journal of Polymer Science Part B:Polymer Physics1991，29，1： | 1 |
| 17 | Disruption of thesleep-wake cycle and diurnal fluctuation of (3-amyloid inmice with Alzheimer,s disease pathology 显示文摘 | Roh J H Huang Y Bero A W | 2012 | Sci TransMed2012，4，15： | 1 |
| 18 | Chemical synthesis and bio-logical screening of 2-aminoimidazole-based bacterial and fungalantibiofilm agents显示文摘 | Rogers S A Bero J D Melander C | 2010 | Chembiochem2010，11，3： | 1 |
| 19 | Moral disengagement in the corpo-rate world 显示文摘 | White J Bandura A Bero L A | 2009 | Accountability in Research2009，，1： | 1 |
| 20 | Pharmaceutical industry sponsorship and research outcome and quality: systematic review显示文摘 | Lexchin J Bero LA Djulbegovic B | 2003 | BMJ2003，326，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员